Beta Bionics CCO sells 5,327 shares for taxes

Beta Bionics’ Chief Commercial Officer sold shares to cover taxes from RSU vesting and still holds over 124,000 shares.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that Chief Commercial Officer Mark Hopman sold 5,327 shares of common stock on September 2, 2026. The sale was made to cover tax withholding obligations arising from the vesting of restricted stock units. The weighted average sale price was $19.1131 per share, within a range of $18.89 to $19.545. After this sale, Hopman continued to hold 124,027 shares of Beta Bionics common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Seller: 5,327 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 5,327 shs ($102K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	5,327	$19.1131	$102K

Holdings After Transaction: Common Stock — 124,027 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. F2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 5,327 shares Weighted average sale price: $19.1131 per share Sale price range: $18.89–$19.545 per share +1 more

4 metrics

Shares sold 5,327 shares Common stock sold by Chief Commercial Officer on September 2, 2026

Weighted average sale price $19.1131 per share Average price for the September 2, 2026 sale

Sale price range $18.89–$19.545 per share Range of prices for the reported sale

Shares held after sale 124,027 shares Direct holdings of Mark Hopman after the September 2, 2026 transaction

Key Terms

weighted average sale price, restricted stock units, tax withholding obligations

3 terms

weighted average sale price financial

"The weighted average sale price for the transaction reported was $19.1131"

restricted stock units financial

"tax withholding obligations associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares were sold to cover tax withholding obligations associated with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BBNX disclose for Chief Commercial Officer Mark Hopman?

BBNX disclosed that Chief Commercial Officer Mark Hopman sold 5,327 shares of common stock on September 2, 2026. The shares were sold to cover tax withholding obligations related to the vesting of restricted stock units.

At what price were the BBNX shares sold in Mark Hopman’s September 2, 2026 transaction?

The filing states a weighted average sale price of $19.1131 per share for Mark Hopman’s sale, with individual trade prices ranging between $18.89 and $19.545 per share.

How many BBNX shares does Mark Hopman hold after the reported sale?

After the reported sale to cover tax withholding, Chief Commercial Officer Mark Hopman directly holds 124,027 shares of Beta Bionics common stock, according to the filing.

Was Mark Hopman’s BBNX share sale under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 trading plan box was not checked, so no Rule 10b5-1 plan is reported for this sale.

Why did Mark Hopman sell BBNX shares on September 2, 2026?

A footnote explains that the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, rather than as a discretionary sale of investment holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:17 PM EDT Accepted by SEC EDGAR 09/03/2026 - 06:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		5,327	D	$19.1131(2)	124,027	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)